Search company, investor...
EveliQure company logo

EveliQure

eveliqure.com

Stage

Seed | Alive

Total Raised

$2.69M

Last Raised

$2.69M | 7 yrs ago

About EveliQure

Provider of vaccine technologies. The company provides a vaccine technology platform based on a live attenuated Shigella strain that is able to induce broad protection against shigellosis caused by different species and serotypes. This vaccine strain serves as a platform to achieve broad coverage of diarrheal pathogens by the designed expression of non-shigella derived antigens. Shigetec™, the first generation vaccine candidate targets Shigella and Enterotoxigenic E. coli (ETEC), the two major causes of diarrhea.

Headquarters Location

Helmut-Qualtinger-Gasse 2 Staircase 1, 3rd floor

Vienna, A-1030,

Austria

Missing: EveliQure's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EveliQure's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

EveliQure Patents

EveliQure has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/5/2013

8/15/2017

Vaccines, Molecular biology, HLA-B alleles, Vaccination, Biotechnology

Grant

Application Date

9/5/2013

Grant Date

8/15/2017

Title

Related Topics

Vaccines, Molecular biology, HLA-B alleles, Vaccination, Biotechnology

Status

Grant

Latest EveliQure News

Traveler's Diarrhea Pipeline Market Insights Report 2022 Featuring Key Players - Nippon Shinyaku, Immuron, Eveliqure Biotechnologies, Lumen Bioscience, Scandinavian Biopharma, & Sigmoid Pharma - ResearchAndMarkets.com

May 25, 2022

This "Traveler's Diarrhea- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Traveler's Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Traveler's Diarrhea- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler's Diarrhea pipeline landscape is provided which includes the disease overview and Traveler's Diarrhea treatment guidelines. The assessment part of the report embraces, in depth Traveler's Diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler's Diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The companies and academics are working to assess challenges and seek opportunities that could influence Traveler's Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Traveler's Diarrhea. Traveler's Diarrhea Emerging Drugs Chapters This segment of the Traveler's Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Traveler's Diarrhea Emerging Drugs IMM124E:Immuron IMM-124E is a first-in class, oral polyclonal antibody therapy developed to target the endotoxin lipopolysaccharide (LPS) and other pathogenic bacterial components in the human gastrointestinal tract reducing LPS-related inflammation and systemic translocation. The drug is in Phase III clinical studies for the treatment of Traveler's diarrhea in individuals traveling to endemic areas for ETEC exposure. LMN101: Lumen Bioscience LMN-101 is a cocktail of neutralizing monoclonal antibody-like protein biologics designed to bind and neutralize the primary causes of traveler's diarrhea: the bacterial pathogens Campylobacter jejuni and enterotoxigenic E. coli. The drug is in Phase II clinical studies for the treatment of Traveler's diarrhea. Traveler's Diarrhea: Therapeutic Assessment This segment of the report provides insights about the different Traveler's Diarrhea drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Traveler's Diarrhea There are approx. 6+ key companies which are developing the therapies for Traveler's Diarrhea. The companies which have their Traveler's Diarrhea drug candidates in the most advanced stage, i.e. Phase III include, Immuron. Phases Late stage products (Phase III) Mid-stage products (Phase II)

EveliQure Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EveliQure Rank

EveliQure Frequently Asked Questions (FAQ)

  • Where is EveliQure's headquarters?

    EveliQure's headquarters is located at Helmut-Qualtinger-Gasse 2, Vienna.

  • What is EveliQure's latest funding round?

    EveliQure's latest funding round is Seed.

  • How much did EveliQure raise?

    EveliQure raised a total of $2.69M.

  • Who are the investors of EveliQure?

    Investors of EveliQure include Arax Capital Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.